NewsRoom Articles - Page 123 of 224

WednesdayMay 18, 2022 1:23 pm

FDA Expands Access to MDMA for Treatment of PTSD

A number of clinics in various cities in America have received approval from the FDA to expand patients’ access to MDMA. MDMA is a psychedelic drug commonly referred to as ecstasy. Researchers have found that this drug may be useful in the treatment of a number of mental health conditions, including post-traumatic stress disorder, or PTSD. While this program is currently in phase III trials, the effectiveness and safety demonstrated thus far will enable the drug to be used for compassionate use. Compassionate use is an approval term used by the FDA for treatments that may help patients who haven’t…

TuesdayMay 17, 2022 3:01 pm

Study Finds Alcohol Cravings Get Stronger After Consumption during Withdrawal

Individuals suffering from alcohol or drug addiction usually have certain cues that set off their cravings. Up until now, researchers weren’t sure how and why environmental cues led to more irresistible cravings. Recent findings show that these new cues are stronger than those learned during the early days of an individual’s alcohol use. This discovery could be helpful in the development of new treatments to reduce cravings in individuals with addictions. Estimates show that more than 14 million individuals in America suffer from alcohol use disorder, which includes various unhealthy drinking behaviors. Similar to other drug addictions, an addiction to…

MondayMay 16, 2022 3:35 pm

Updated Guidelines Shed Light on Using Radiation Against Brain Metastases

The American Society for Radiation Oncology recently released a new clinical guideline that offers guidance on how radiation therapy should be used when treating brain metastases. Brain metastases are tumors that develop when cancer cells from a primary tumor located in another part of the body — mostly melanoma, breast cancer or lung cancer — spread to a patient’s brain. These tumors develop in about 40% of individuals who have already been diagnosed with cancer, with almost 200,000 new cases being diagnosed annually in America. Radiation therapy is usually used to manage these brain tumors, providing patients relief from dizziness, headaches and…

MondayMay 16, 2022 10:30 am

Aditxt Inc. (NASDAQ: ADTX) Is ‘One to Watch’

Aditxt is commercializing new innovations with focus on mapping and reprogramming the immune system Aditxt is actively adding distribution channel partners for AditxtScore(TM) throughout the U.S. and globally The company aims to expand reimbursement coverage for AditxtScore(TM) for COVID-19 from private insurance and public payers while developing and commercializing tests for other indications Aditxt intends to advance its ADi(TM) therapeutics pipeline into clinical trials in the coming months, with initial studies targeting psoriasis, type 1 diabetes, and skin allograft transplantation The company is led by a team of experts coming from a variety of different scientific fields and business backgrounds…

FridayMay 13, 2022 2:10 pm

Researchers Have Found Brain Cells That Die Due to Parkinson’s Disease

Parkinson’s disease is a brain disorder that causes uncontrollable or unintended movements, such as stiffness, shaking and difficulty with coordination and balance. The disorder’s symptoms worsen over time as the disease progresses, with patients finding it difficult to even talk and walk when the disease is in its advanced stages. Estimates show that almost one million individuals in America suffer from Parkinson’s disease. New research has identified the brain cells susceptible to Parkinson’s disease, and this could help scientists have a better understanding of how this debilitating illness takes hold and perhaps identify ways to prevent its progression. Researchers have…

ThursdayMay 12, 2022 12:59 pm

Study Discovers Mechanisms Behind Relapse After Treatment of MDD

A new study has discovered abnormalities in neural emotional regulation in individuals suffering from remitted major depressive disorder (MDD). The study’s findings highlight some neural mechanisms that may play a role in relapse. The author of the study, Rozemarijn S. van Kleef, stated that the interest in this role arose from the fact that depression recurring after remission was a huge issue on a societal as well as a personal level. A psychological therapist, van Kleef explained that it was crucial to gain more insight into the mechanisms underlying this recurrence, giving the examples of prior studies, which had found…

WednesdayMay 11, 2022 11:36 am

Researchers Develop Models to Better Understand Brain Cancer Metastasis

When cancer cells spread to the brain, they lead to the formation of brain metastases. Metastases are the primary cause of mortality and morbidity linked to cancer. Researchers at Instituto de Medicina Molecular have developed models to study brain metastases, which may help to better understand cancer and find new treatment approaches that can be modified to fit the needs of every patient. For their study, the researchers gathered brain metastases from patients with cancer that arose from tumors located in other organs. They used these cells to generate ailment models that mimicked the illness of every patient. The scientists…

WednesdayMay 11, 2022 11:15 am

Silo Pharma Inc. (SILO) Spotlight: Ketamine

Ketamine shows promise in treating Alzheimer’s Disease, Parkinson’s Disease as well as depression, suicide ideation and more In 2021, Silo Pharma (OTCQB: SILO) entered into a joint venture with Zylö Therapeutics to “explore the clinical development of ketamine using ZTI’s Z-pod (transdermal) technology.” This innovative technology allows Silo, an early-stage biopharmaceutical company, to develop a ketamine delivery system for those suffering dysphagia, a difficulty or complete inability to swallow.(1) Silo Pharma is exploring the efficacy of ketamine in treating patients suffering from both Alzheimer’s Disease (“AD”) and Parkinson’s Disease (“PD”). Over 80% of PD patients(2) and 75% of AD patients(3)…

WednesdayMay 11, 2022 10:30 am

Investor Event Turns Spotlight on Novel Brain Cancer Drug Candidate Global Trial Under Way by CNS Pharmaceuticals, Inc. (NASDAQ: CNSP)

CNS Pharmaceuticals is developing a proprietary drug candidate that has the potential to deliver a novel solution for unmet medical needs in treating an incurable brain cancer CNS’s drug candidate is called Berubicin, a powerful anthracycline that appears to be the first such chemotherapy agent able to successfully cross the blood-brain barrier Berubicin dosing has begun in a potentially pivotal global trial that is recruiting glioblastoma multiforme (“GBM”) brain cancer patients The FDA has granted CNS fast-track authorization in regard to Berubicin’s development, and European countries’ drug regulatory bodies are also granting authorization to advance the trial process there An…

TuesdayMay 10, 2022 3:09 pm

Study Finds Service Dogs Help Individuals with PTSD

Post-traumatic stress disorder is a mental health disorder brought on by experiencing or witnessing a traumatic or terrifying event. This condition may last a few months or even years, with triggers unearthing traumatic memories and causing intense physical and emotional reactions. To help manage the condition’s symptoms, patients are sometimes assigned a buddy dog to be their companion during their daily activities. For a long time, patients with post-traumatic stress disorder have argued that a buddy dog helped better their lives. However the lack of scientific evidence made it hard to substantiate these claims — until now. A new study…